Quick Facts
Plain-English Summary
The Metabolic Blend combines three compounds with radically different evidence profiles under a single vial. Semaglutide is an FDA-approved GLP-1 receptor agonist with a substantial Phase III human trial record, including the landmark STEP-1 trial showing approximately 15% mean body weight reduction. AOD-9604 is a synthetic fragment of human growth hormone (residues 177–191) that completed a Phase II trial in obesity but was never approved as a drug; it holds GRAS status as a food ingredient in the United States, which is not equivalent to pharmaceutical approval. 5-Amino-1MQ is a small-molecule NNMT inhibitor studied exclusively in mouse models, with no published human safety or efficacy data as of 2026.
No study — peer-reviewed or otherwise — has examined the combination of these three agents. Their pharmacokinetic interactions, combined tolerability profile, and whether co-administration produces additive, synergistic, or antagonistic effects on metabolic pathways is entirely unknown. Vendor claims of superior fat loss compared to Semaglutide alone have no scientific basis.
The Metabolic Blend is the most evidence-mismatched compound in this library. Administering an FDA-approved drug (at a non-standard dose, via a non-approved route) alongside a non-approved GH fragment and a preclinical-only research chemical creates a risk profile that cannot currently be assessed. No safety data exists for this combination in any species.
The Semaglutide dose in this blend (5 mg) is substantially higher than approved therapeutic doses (0.25–2.4 mg/week for Wegovy; 0.25–2 mg/week for Ozempic). The pharmacodynamic implications of this dose when co-administered with the other components are unknown. Individual compound assessments should be consulted alongside this blend profile.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|
Metabolic Blend has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
At approved doses, Semaglutide's most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. Risk of pancreatitis, medullary thyroid carcinoma (boxed warning in rodents — human relevance uncertain), and hypoglycaemia when combined with other glucose-lowering agents. The safety profile at 5 mg (the dose in this blend) is not established; approved doses are 0.25–2.4 mg/week.
Phase II trials reported no significant adverse effects compared to placebo at doses up to 1 mg/day. GRAS classification does not imply safety at injectable doses. No long-term human safety data. No pharmacovigilance database exists for injectable AOD-9604 use.
- No human safety data exists
- No dose-ranging studies in any species
- NAD+ pathway modulation may have broad metabolic consequences
- No pharmacovigilance data
- No regulatory body has reviewed it as a therapeutic
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Active or suspected malignancy
- Pregnancy or breastfeeding
- Existing GI conditions (pancreatitis, gastroparesis)
- Current use of any diabetes or weight management medication
Metabolic Blend is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Metabolic Blend for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume